INBXInhibrx Biosciences, Inc.
Price
+245%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Nothing alarming, growth fading, the market undecided.
We are a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using our proprietary modular protein engineering platforms. We leverage our innovative protein engineering technologies and deep understanding of target biology to create therapeutic candidates with attributes and mechanisms we believe to be superior to current approaches and applicable to a range of challenging, validated targets with high potential.
In the company’s own words · 10-K filed Mar 19, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Inhibrx Biosciences, Inc. (INBX) reported revenue of $0 in Q2 2026 (quarter ended Jun 30, 2026), down 100% from the same quarter a year earlier. That came with net loss of $37M. For the full year FY2025, revenue was $1.3M (+550% year on year) and net income −$140M. The next results filing is expected around Nov 13, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 8, 2026Updated Phase 2 Data for INBRX-106 in First-Line HNSCC On September 8, 2026, Inhibrx announced the primary endpoint results from the randomized and controlled Phase 2 portion of its HexAgon study, which is evaluating the safety and efficacy of INBRX-106, a hexavalent OX40 agonist, in combination with pembrolizumab …Regulation FD disclosure · Form 8-K
- Aug 13, 2026Inhibrx Reports Second Quarter 2026 Financial Results.Earnings release · press release
- Jul 16, 2026On July 15, 2026, Inhibrx Biosciences, Inc. (the “Company”), Oxford Finance LLC as collateral agent (“Collateral Agent”), and the other lenders party thereto (the “Lenders”), entered into a second amendment (the “Second Amendment”) to the Loan and Security Agreement dated as of January 13, 2025, as amended by the …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Biotechnology
The closest names by size in the same industry